ADEFOVIR DIPIVOXIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H32N5O8P
Molecular Weight	501.4705
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C

InChI

InChIKey=WOZSCQDILHKSGG-UHFFFAOYSA-N

InChI=1S/C20H32N5O8P/c1-19(2,3)17(26)30-11-32-34(28,33-12-31-18(27)20(4,5)6)13-29-8-7-25-10-24-14-15(21)22-9-23-16(14)25/h9-10H,7-8,11-13H2,1-6H3,(H2,21,22,23)

HIDE SMILES / InChI

Description

The potential antiviral effect of adefovir, an acyclic nucleoside phosphonate analog of 2′-deoxyadenosine monophosphate, was first studied by Holý and De Clercq in 1980s. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. Oral adefovir dipivoxil is effective and generally well tolerated in HBeAg-positive and -negative patients chronically infected with wild-type or lamivudine-resistant HBV.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Multidrug resistance-associated protein 4 14	Inhibitor 8,297	133.0 µM [IC50]
Bile salt export pump 15	Inhibitor 8,297	46.0 µM [IC50]
Canalicular multispecific organic anion transporter 1 21	Inhibitor 8,297	133.0 µM [IC50]
Canalicular multispecific organic anion transporter 2 8	Inhibitor 8,297	133.0 µM [IC50]
DNA polymerase/reverse transcriptase 10	Inhibitor 8,297	0.1 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic hepatitis B 16	Primary		Approved 8,429	HEPSERA

C_max

Value	Dose	Co-administered	Analyte	Population
18.4 ng/mL	10 mg single, oral		ADEFOVIR plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
220 ng × h/mL	10 mg single, oral		ADEFOVIR plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
7.48 h	10 mg single, oral		ADEFOVIR plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
96%	10 mg single, oral		ADEFOVIR plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Recommended	unhealthy, 12 - 17 years n = 15	Other AEs: Rhinorrhea, Sneezing...
0.3 mg/kg 1 times / day multiple, oral Recommended	unhealthy, 2 - 6 years n = 13
0.3 mg/kg 1 times / day multiple, oral Recommended	unhealthy, 7 - 11 years n = 19	Other AEs: Headache, Vertigo...

Showing 1 to 3 of 3 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Blister	1 patient	10 mg 1 times / day multiple, oral Recommended	unhealthy, 12 - 17 years n = 15
Rhinorrhea	1 patient	10 mg 1 times / day multiple, oral Recommended	unhealthy, 12 - 17 years n = 15
Sneezing	1 patient	10 mg 1 times / day multiple, oral Recommended	unhealthy, 12 - 17 years n = 15
Disorder eye	1 patient	0.3 mg/kg 1 times / day multiple, oral Recommended	unhealthy, 7 - 11 years n = 19
Disturbance in attention	1 patient	0.3 mg/kg 1 times / day multiple, oral Recommended	unhealthy, 7 - 11 years n = 19

Showing 1 to 5 of 7 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1,587 substrate 1,737	inhibitor 1,767 substrate 1,037	inhibitor 1,852 substrate 1,217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1,524 CYP2C19 1,478 P-gp 1,461	OAT1 326 OCT2 355 MRP4 77 CYP1A2 1,054 CYP2C19 991 P-gp 1,537	CYP 76

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP 147	inducer 1,573	inconclusive
P-gp 1,650	inhibitor 3,277	inconclusive
CYP1A2 1,692	inhibitor 3,277	no
CYP2C19 1,553	inhibitor 3,277	no
CYP2C9 1,819	inhibitor 3,277	no

Showing 1 to 5 of 7 entries

Previous1 2Next

Drug as victim

Show entries

Target	Modality	Activity
P-gp 1,537	substrate 3,367	inconclusive
CYP1A2 1,054	substrate 3,367	no
CYP2C19 991	substrate 3,367	no
CYP2C9 1,037	substrate 3,367	no
CYP2D6 1,217	substrate 3,367	no

Showing 1 to 5 of 9 entries

Previous1 2Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2469	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2469
ChemicalBook	CB2698137	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2698137
ZINC	ZINC000021297308	http://zinc15.docking.org/substances/ZINC000021297308
eMolecules	901335	https://www.emolecules.com/cgi-bin/more?vid=901335

Showing 1 to 4 of 4 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine.	1991 Jan 5	1845964
Effect of acyclic nucleoside phosphonates on the HIV-1 integrase in vitro.	1999 Apr-May	10432692
Selective activity of various antiviral compounds against HHV-7 infection.	1999 Aug	10480261
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.	1999 Jun	10377169
Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.	1999 Jun 15	10353255

Showing 1 to 5 of 31 entries

Previous1 2 3 4 5 6 7Next

Patents

Sample Use Guides

In Vivo Use Guide

One tablet containing 10 mg adefovir dipivoxil once daily orally

Route of Administration: Oral

In Vitro Use Guide

The concentration of adefovir that inhibited 50% of viral DNA synthesis (EC50) in HBV transfected human hepatoma cell lines ranged from 0.2 to 2.5 uM.

Show entries

Name

Type

Language

ADEFOVIR DIPIVOXIL

Official Name

English

ADEFOVIR DIPIVOXIL [VANDF]

Common Name

English

ADEFOVIR PIVOXIL [JAN]

Common Name

English

GS-0840

Code

English

PROPANOIC ACID, 2,2-DIMETHYL-, (((2-(6-AMINO-9H-PURIN-9-YL)ETHOXY)METHYL)PHOSPHINYLIDENE)BIS(OXYMETHYLENE) ESTER

Common Name

English

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

Show entries

Classification Tree

Code System

Code

HEPTATIS, CHRONIC

EMA ASSESSMENT REPORTS

HEPSERA (AUTHORIZED: HEPTATIS B, CHRONIC)

Nucleoside and nucleotide reverse transcriptase inhibitors

WHO-VATC

QJ05AF08

Nucleoside and nucleotide reverse transcriptase inhibitors

WHO-ATC

J05AF08

Reverse Transcriptase Inhibitor

NCI_THESAURUS

C97452

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

SMS_ID

100000093015

PRIMARY

EVMPD

SUB12454MIG

PRIMARY

EPA CompTox

DTXSID5046487

PRIMARY

FDA UNII

U6Q8Z01514

PRIMARY

DRUG BANK

DB00718

PRIMARY

Showing 1 to 5 of 16 entries

Previous1 2 3 4Next

ACTIVE MOIETY


					6GQP90I798

ADEFOVIR

SUBSTANCE RECORD


					U6Q8Z01514

ADEFOVIR DIPIVOXIL

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator